Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen

US8431134B2 · kind B2 · utility

Assignee

• The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · US

Inventors

• Edwin W. Ades · Atlanta, US
• Gowrisankar Rajam · Tucker, US
• Sandra Steiner · Atlanta, US
• George M. Carlone · Stone Mountain, US
• Nikkoj Melnick · Braselton, US
• Jacquelyn S. Sampson · College Park, US
• Joseph E. Martinez · Boonton, US
• Julie M. Skinner · Phoenixville, US

Key dates

• Filing date: Jul 31, 2009
• Grant date: Apr 30, 2013
• Expiry date: Aug 14, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.